

# Invitation to the presentation of SenzaGen's Q2 2025 interim report

Lund, August 14, 2025

**SenzaGen's 2025 Q2 report will be published on Aug 20, 2025, at 07:30 AM, followed by a live webcast presentation at 10:00 on the same day. The presentation will be given by SenzaGen's President and CEO, Peter Nählstedt, with a subsequent Q&A session moderated by Rodney Alfvén, partner at Hallvarsson & Halvarsson.**

**Time:** Wednesday, Aug 20, 10:00

## *Webcast*

If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions:

<https://senzagen.events.inderes.com/q2-report-2025>

## *Teleconference*

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference:

<https://events.inderes.com/senzagen/q2-report-2025/dial-in>

The presentation can also be viewed later on SenzaGen's website: <https://senzagen.com/investors/presentations/>

## **Contacts**

---

**Peter Nählstedt**, President and CEO, SenzaGen AB

Email: [peter.nahlstedt@senzagen.com](mailto:peter.nahlstedt@senzagen.com) | Tel: +46 46-275 62 00

**Tina Dackemark Lawesson**, VP Marketing & Communications

Email: [tina.lawesson@senzagen.com](mailto:tina.lawesson@senzagen.com) | Tel: +46 46-275 62 00



## About us

---

SenzaGen is a corporate group committed to becoming a leading player in non-animal testing, driving the shift from animal experiments to methods that more accurately reflect human biology. Leveraging cutting-edge technology, the company offers high-performance non-animal test methods and expert advisory services. These methods are more effective, precise, and cost-efficient than traditional animal-based approaches, while also helping to reduce the use of laboratory animals. SenzaGen's growth strategy focuses on strengthening its position in both established and new markets through direct sales, complementary partnerships, an expanded test portfolio, and recognized thought leadership. The company also maintains a long-term acquisition agenda to expand its capabilities. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden, along with subsidiaries in Italy and the USA. For more information, visit [www.senzagen.com](http://www.senzagen.com).

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

## Attachments

---

[Invitation to the presentation of SenzaGen's Q2 2025 interim report](#)